Last €108.05 EUR
Change Today +0.61 / 0.57%
Volume 0.0
J7Z On Other Exchanges
As of 2:08 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

jazz pharmaceuticals plc (J7Z) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/24/14 - €128.53
52 Week Low
07/25/13 - €53.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for JAZZ PHARMACEUTICALS PLC (J7Z)

jazz pharmaceuticals plc (J7Z) Related Businessweek News

No Related Businessweek News Found

jazz pharmaceuticals plc (J7Z) Details

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients. In addition, it offers products in the areas of hematology and oncology drugs, such as Asparec, which is in Phase I clinical trial for the treatment of patients with ALL with E.coli asparaginase hypersensitivity; Defibrotide for the treatment of severe VOD; and Leukotac, an anti-CD25 monoclonal antibody that is in Phase III clinical trials and is intended for the treatment of steroid-refractory acute GvHD. The company is headquartered in Dublin, Ireland.

815 Employees
Last Reported Date: 05/8/14

jazz pharmaceuticals plc (J7Z) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: $771.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $419.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $547.0K
Executive Vice President and General Counsel
Total Annual Compensation: $536.0K
Total Annual Compensation: $472.7K
Compensation as of Fiscal Year 2013.

jazz pharmaceuticals plc (J7Z) Key Developments

Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc. Provide Phase 1 Clinical Trial Update on JZP-386

Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc. announced the initiation of the first Phase 1 clinical trial of JZP-386, a deuterium-containing analog of sodium oxybate--the active ingredient in Xyrem (sodium oxybate) oral solution. The Phase 1 clinical trial is designed to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JZP-386, and includes Xyrem as an active control. The study is expected to enroll up to 28 healthy subjects at a single center in Europe. The results of the study are intended to assess the PK/PD profile of JZP-386 to identify a safe and tolerable dose or doses of JZP-386 that could be used in subsequent clinical trials and to determine whether JZP-386 is suitable for once nightly dosing. Under its 2013 agreement with Concert, Jazz Pharmaceuticals has worldwide rights to develop and commercialize JZP-386. Concert has the potential to realize milestone payments upon meeting development objectives and tiered royalties on any worldwide sales. Jazz Pharmaceuticals and Concert are working collaboratively on development of JZP-386, and Concert is responsible for conducting clinical activities for JZP-386 through Phase 1.

Jazz Pharmaceuticals Public Limited Company - Special Call

To discuss the transaction to acquire Sigma-Tau rights to defibrotide in the United States (U.S.) and all other countries in the Americas

Jazz Pharmaceuticals plc Announces Resignation of Fintan Keegan as Executive Vice President, Technical Operations, Effective August 11, 2014

Jazz Pharmaceuticals plc announced that on May 30, 2014, Fintan Keegan informed his decision to resign from his position as Executive Vice President, Technical Operations of the Company, which resignation will be effective as of August 11, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
J7Z:GR €108.05 EUR +0.61

J7Z Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $34.48 USD +0.45
Alkermes PLC $45.42 USD -0.49
BioMarin Pharmaceutical Inc $60.38 USD +1.02
Impax Laboratories Inc $29.01 USD +0.07
Salix Pharmaceuticals Ltd $131.26 USD +1.12
View Industry Companies

Industry Analysis


Industry Average

Valuation J7Z Industry Range
Price/Earnings 100.0x
Price/Sales 9.3x
Price/Book 7.0x
Price/Cash Flow 50.9x
TEV/Sales 7.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at